Taking a Toll on the bones: Regulation of bone metabolism by innate immune regulators

References

• Henderson B, Nair SP. Hard labour: Bacterial infection of the skeleton. Trends Microbiol 2003; 11: 570–577
   Web of Science ®Google Scholar
• Ciampolini J, Harding KG. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often?. Postgrad Med J 2000; 76: 479–483
   PubMed Web of Science ®Google Scholar
• Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 86: 973–983
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394–397
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783–801
   PubMed Web of Science ®Google Scholar
• West AP, Koblansky AA, Ghosh S. Recognition and signaling by Toll-like receptors. Annu Rev Cell Dev Biol 2006; 22: 409–437
   PubMed Web of Science ®Google Scholar
• Wu H, Arron JR. TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology. Bioessays 2003; 25: 1096–1105
   PubMed Web of Science ®Google Scholar
• Dempster DW. Anatomy and functions of the adult skeleton. Primer on the metabolic bone diseases and disorders of mineral metabolism6th ed., MJ Favus. American Society for Bone and Mineral Research, Washington DC 2006; 7–11
   Google Scholar
• Aubin JE, Lian JB, Stein GS. Bone formation: Maturation and functional activities of osteoblast lineage cells ibid 2006. p 20–29
   Google Scholar
• Ross FP. Osteoclast biology and bone resorption ibid 2006. p 30–35
   Google Scholar
• Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337–342
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003; 4: 638–649
   PubMed Web of Science ®Google Scholar
• Weitzmann MN, Pacifici R. The role of T lymphocytes in bone metabolism. Immunol Rev 2005; 208: 154–168
   PubMed Web of Science ®Google Scholar
• Takayanagi H, Sato K, Takaoka A, Taniguchi T. Interplay between interferon and other cytokine systems in bone metabolism. Immunol Rev 2005; 208: 181–193
   PubMedGoogle Scholar
• Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, Choi Y. Osteoimmunology: Interplay between the immune system and bone metabolism. Annu Rev Immunol 2006; 24: 33–63
   PubMed Web of Science ®Google Scholar
• Xing L, Schwarz EM, Boyce BF. Osteoclast precursors, RANKL/RANK and immunology. Immunol Rev 2005; 208: 19–29
   PubMed Web of Science ®Google Scholar
• Takayanagi H. Osteoimmunology: Shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007; 7: 292–304
   PubMed Web of Science ®Google Scholar
• Weir EC, Insogna KL, Horowitz MC. Osteoblast-like cells secrete granulocyte-macrophage colony-stimulating factor in response to parathyroid hormone and lipopolysaccharide. Endocrinology 1989; 124: 899–904
   Google Scholar
• Horowitz MC, Coleman DL, Flood PM, Kupper TS, Jilka RL. Parathyroid hormone and lipopolysaccharide induce murine osteoblast-like cells to secrete a cytokine indistinguishable from granulocyte-macrophage colony-stimulating factor. J Clin Invest 1989; 83: 149–157
   PubMed Web of Science ®Google Scholar
• Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL–RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006; 12: 17–25
   PubMed Web of Science ®Google Scholar
• Feng X. RANKing intracellular signaling in osteoclasts. IUBMB Life 2005; 57: 389–395
   PubMed Web of Science ®Google Scholar
• Wagner H. The immunobiology of the TLR9 subfamily. Trends Immunol 2004; 25: 381–386
   PubMed Web of Science ®Google Scholar
• Krieg AM. Now I know my CpGs. Trends Microbiol 2001; 9: 249–252
   Google Scholar
• Zou W, Schwartz H, Endres S, Hartmann G, Bar-Shavit Z. CpG oligonucleotides: Novel regulators of osteoclast differentiation. FASEB J 2002; 16: 274–282
   Google Scholar
• Zou W, Bar-Shavit Z. Dual modulation of osteoclast differentiation by lipopolysaccharide. J Bone Miner Res 2002; 17: 1211–1218
   PubMedGoogle Scholar
• Takami M, Kim N, Rho J, Choi Y. Stimulation by Toll-like receptors inhibits osteoclast differentiation. J Immunol 2002; 169: 1516–1523
   PubMed Web of Science ®Google Scholar
• Hayashi S, Yamada T, Tsuneto M, Yamane T, Takahashi M, Shultz LD, Yamazaki H. Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha. J Immunol 2003; 171: 5130–5139
   Web of Science ®Google Scholar
• Abu-Amer Y, Ross FP, Edwards J, Teitelbaum SL. Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. J Clin Invest 1997; 100: 1557–1565
   PubMedGoogle Scholar
• Amcheslavsky A, Zou W, Bar-Shavit Z. Toll-like receptor 9 regulates tumor necrosis factor-alpha expression by different mechanisms. Implications for osteoclastogenesis. J Biol Chem 2004; 279: 54039–54045
   Google Scholar
• Itoh K, Udagawa N, Kobayashi K, Suda K, Li X, Takami M, Okahashi N, Nishihara T, Takahashi N. Lipopolysaccharide promotes the survival of osteoclasts via Toll-like receptor 4, but cytokine production of osteoclasts in response to lipopolysaccharide is different from that of macrophages. J Immunol 2003; 170: 3688–3695
   PubMed Web of Science ®Google Scholar
• Ueda N, Koide M, Ohguchi M, Ishihara Y, Noguchi T, Okahashi N, Nishihara T. Involvement of prostaglandin E2 and interleukin-1 alpha in the differentiation and survival of osteoclasts induced by lipopolysaccharide from Actinobacillus actinomycetemcomitans Y4. J Periodontal Res 1998; 33: 509–516
   PubMedGoogle Scholar
• Jiang J, Zuo J, Hurst IR, Holliday LS. The synergistic effect of peptidoglycan and lipopolysaccaride on osteoclast formation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 96: 738–743
   Google Scholar
• Kadono Y, Okada F, Perchonock C, Jang HD, Lee SY, Kim N, Choi Y. Strength of TRAF6 signalling determines osteoclastogenesis. EMBO Rep 2005; 6: 171–176
   PubMed Web of Science ®Google Scholar
• Horwood NJ, Elliott J, Martin TJ, Gillespie MT. IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol 2001; 166: 4915–4921
   PubMed Web of Science ®Google Scholar
• Amcheslavsky A, Bar-Shavit Z. Interleukin (IL)-12 mediates the anti-osteoclastogenic activity of CpG-oligodeoxynucleotides. J Cell Physiol 2006; 207: 244–250
   Google Scholar
• Amcheslavsky A, Bar-Shavit Z. Toll-like receptor 9 ligand blocks osteoclast differentiation via induction of phosphatase. J Bone Min Res 2007; 22: 1301–1310
   Web of Science ®Google Scholar
• Rüther U, Garber C, Komitowski D, Müller R, Wagner EF. Deregulated c-fos expression interferes with normal bone development in transgenic mice. Nature 1987; 325: 412–416
   PubMed Web of Science ®Google Scholar
• Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol 2002; 4: 556–564
   PubMed Web of Science ®Google Scholar
• Roy S, Charboneau R, Melnyk D, Barke RA. Interleukin-4 regulates macrophage interleukin-12 protein synthesis through a c-fos mediated mechanism. Surgery 2000; 128: 219–224
   Google Scholar
• Marriott I. Osteoblast responses to bacterial pathogens: A previously unappreciated role for bone-forming cells in host defense and disease progression. Immunol Res 2004; 30: 291–308
   Google Scholar
• Kikuchi T, Matsuguchi T, Tsuboi N, Mitani A, Tanaka S, Matsuoka M, Yamamoto G, Hishikawa T, Noguchi T, Yoshikai Y. Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. J Immunol 2001; 166: 3574–3579
   PubMedGoogle Scholar
• Zou W, Amcheslavsky A, Bar-Shavit Z. CpG oligodeoxynucleotides modulate the osteoclastogenic activity of osteoblasts via Toll-like receptor 9. J Biol Chem 2003; 278: 16732–16740
   Google Scholar
• Amcheslavsky A, Hemmi H, Akira S, Bar-Shavit Z. Differential contribution of osteoclast- and osteoblast-lineage cells to CpG-oligodeoxynucleotide (CpG–ODN) modulation of osteoclastogenesis. J Bone Miner Res 2005; 20: 1692–1699
   Web of Science ®Google Scholar
• Van Zant G. Studies of hematopoietic stem cells spared by 5-fluorouracil. J Exp Med 1984; 159: 679–690
   PubMed Web of Science ®Google Scholar
• Walsh NC, Crotti TN, Goldring SR, Gravallese EM. Rheumatic diseases: The effects of inflammation on bone. Immunol Rev 2005; 208: 228–251
   PubMed Web of Science ®Google Scholar
• Wagner H. Endogenous TLR ligands and autoimmunity. Adv Immunol 2006; 91: 159–173
   PubMed Web of Science ®Google Scholar
• Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6: 823–835
   PubMed Web of Science ®Google Scholar
• Hoebe K, Jiang Z, Tabeta K, Du X, Georgel P, Crozat K, Beutler B. Genetic analysis of innate immunity. Adv Immunol 2006; 91: 175–226
   Google Scholar
• Lane NE. Therapy insight: Osteoporosis and osteonecrosis in systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006; 2: 562–569
   Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 471–484
   PubMed Web of Science ®Google Scholar